Brokerages Set Urogen Pharma (NASDAQ:URGN) PT at $39.50

Urogen Pharma (NASDAQ:URGN) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $39.50.

URGN has been the subject of several research analyst reports. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. HC Wainwright reiterated a “buy” rating on shares of Urogen Pharma in a report on Thursday. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research report on Tuesday, March 31st.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares of the company’s stock, valued at approximately $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,222 shares of company stock worth $892,661 over the last 90 days. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of Urogen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. Paradigm Biocapital Advisors LP raised its stake in Urogen Pharma by 6.1% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock worth $104,773,000 after buying an additional 257,564 shares during the period. Morgan Stanley grew its stake in Urogen Pharma by 1.4% in the fourth quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock valued at $60,023,000 after acquiring an additional 34,455 shares during the period. Soleus Capital Management L.P. bought a new stake in shares of Urogen Pharma during the second quarter valued at approximately $29,934,000. SG Americas Securities LLC increased its holdings in shares of Urogen Pharma by 20.3% during the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after acquiring an additional 280,199 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Urogen Pharma during the fourth quarter worth approximately $26,350,000. 91.29% of the stock is owned by institutional investors.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN traded down $1.67 during trading on Friday, reaching $38.56. The stock had a trading volume of 1,281,162 shares, compared to its average volume of 656,502. Urogen Pharma has a 52 week low of $13.79 and a 52 week high of $40.35. The firm’s fifty day moving average is $31.28 and its 200 day moving average is $24.43. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -14.02 and a beta of 1.56.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The firm had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. On average, research analysts forecast that Urogen Pharma will post -0.88 earnings per share for the current fiscal year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.